Index

‘Note: Page numbers in *italics* refer to Figures; those in **bold** to Tables’

acidosis, 106, 134, 152, **154**, 161
ACTH. *see* adrenocorticotrophin hormone (ACTH)
AD. *see* Alzheimer disease (AD)
adrenocorticotrophin hormone (ACTH), 27–8, 182
adult epilepsy, dietary treatment, 189–97
anticonvulsant medications, 189
barriers, 196–7
enteral feeding, 194–6
implementation, adult KD therapy, 192–3
increasing demand, 190–191
indications and contraindications, 191
MAD. *see* modified Atkins diet (MAD)
mental conception, 190
seizure frequency, 189
standardized stepwise approach, 194, 195
studies, KD therapy, 189, **190**
weight loss, 190
AEDs. *see* antiepileptic drugs (AEDs)
ageing, 227
Alzheimer disease (AD), 225–6
amyotrophic lateral sclerosis (ALS), 227
antiepileptic drugs (AEDs)
  bone remodelling, 160
description, 17
drug interactions, 20
side effects, **20**
antipyretics and analgesia, 140–141
ASD. *see* autistic spectrum disorder (ASD)
autistic spectrum disorder (ASD)
  management, feeding problems, 63
  selective eaters, 61–2
blood measurement of ketosis
  abnormal/inaccurate results, 137
  infants, 186–7
  instructions, meter, 136, 137
  limitations, 137–8
  seizure control, 137
blood glucose monitoring, 132, 138, 186–7
bone health and dietary treatments, 159–65
epilepsy, fractures and AEDs, 160
KD
  bone mineral content (BMC), 161–2
  vitamin D status, 161
  modified diets, 162

*Dietary Treatment of Epilepsy: Practical Implementation of Ketogenic Therapy*,
First Edition. Edited by Elizabeth Neal.
© 2012 John Wiley & Sons, Ltd. Published 2012 by John Wiley & Sons, Ltd.
bone health and dietary treatments (cont’d)
monitoring
  DEXA screening, 162
vitamin D, 163
nutrition and physical activity, 160–161
osteoporosis. see osteoporosis
peak bone mass, 160
cancer, 228–9
carnitine, 166–71, 217
description, 166
and KD, 168
metabolic pathways, 167
status assessment and supplementation, 169–70
centile charts, 60, 152
classical KD. see ketogenic diet,
classical KD
constipation, 106, 130, 153–5, 153
daVinci syrups, 120
DBS. see deep brain stimulation (DBS)
Deep brain stimulation (DBS), 21–2
DEXA. see dual-energy X-ray absorptiometry (DEXA)
dietary initiation, 131–4
blood glucose and ketone levels
carbonic anhydrase inhibitor medications, 134
excess ketosis, 134
hypoglycaemia, 132, 134
protocols and calculation methods, 131–3
dietary treatments, management, 109–23
away from home, 120–122
diet preparation, 117–18
everyday problems, 122–3
fluids, 112
food allergy/intolerance, 113, 114
free foods, sweeteners and sugar alcohols, 111
low-carbohydrate meal tips, 120, 121
parental fears and anxieties, 116–17
reading labels, 112, 112
shopping, 118–19
special occasions, 113
topical creams and toothpaste,
  113–14
vitamins, minerals and trace elements. see micronutrient supplementation
dietary unit, 69, 70
discontinuation, dietary treatments,
  173–7
classical KD, 176
MAD and LGIT, 177
MCT KD, 177
planning, 175–6
Doose syndrome, 28–9
dual-energy X-ray absorptiometry (DEXA)
  BMC measurement, 161
  KD, 162
EEG. see Electroencephalogram (EEG)
EFA. see essential fatty acids (EFA)
efficacy, KD therapy, 24–33
ages older than childhood, 29–30
gastrostomy tubes, 28
MAD and LGIT, 28
MCT and classical diets, 6, 26
multiple studies, 25, 26
randomized controlled trials, 25
retrospective and prospective studies, 24, 25
seizure syndromes and types, 27–8
Electroencephalogram (EEG)
electroclinical characteristics, 15
epileptic seizures, 13
generalized spike wave activity, 14
childhood absence epilepsy, 14
Electronic Ketogenic Manager (EKM), 71
enteral feeding, 124–30
calculation, classical KD enteral feeds, 125, 126
constipation, 130
jejunal feeding, 129–30
ketogenic formulas, adults, 194, 196
MAD, 129
MCT KD, 127–8
reflux, 129
transition
Ketocal quantity, 127
ketogenic feeds, reduced ratio, 125, 127
percentage, existing enteral feeds, 125, 126
weaning, enteral feed, 130
epilepsy and epileptic seizures, 11–18
description, 11
diagnosis
defined, 11
EEG, 13, 14
misdiagnosis rate, 12
MRI, 13
prevalence and incidence, 13
prognosis, 17–18
surgery, 21
syndromes and seizure types
classification, 13, 15, 16
clinical presentation, 15
cortical malformations, 15
defined, 13, 15
SCN1A mutations, 16
treatment options, 16–17, 19–23
essential fatty acids (EFA), 110–111, 218
fat absorption and metabolism, 35, 36, 37
fat-soluble vitamins, 111, 151
feeding difficulties
behavioural, 61–3
physical, 58–60
fine tuning dietary treatments, 142–8
carbohydrate manipulation, 144–6
energy manipulation, 147–8
fat manipulation, 146–7
protein manipulation, 143–4
food intolerance, epilepsy, 7
food labels, 112, 112
FruitiVits, 109–10, 234
gastrointestinal side effects, KD, 153–5, 154
hyperketosis, 134, 144, 145, 186–7
hypoglycaemia, 132, 134, 144
hypomagnesaemia, 151
ILAE. see International League Against Epilepsy (ILAE)
ilness management
anaesthesia, 139
fever, 139
medications
antipyretics and analgesia, 140–141
carbohydrate content, 140
‘emergency’, 140
vomiting/diarrhoea, 138–9
infant epilepsy, dietary treatment, 181–8
formulas, 183–4, 185
implementation, 184–6
monitoring, 186
safety and efficacy, 181
vitamin drops, 185–6
weaning, 186
infantile spasms (IS), 182–3
International League Against Epilepsy (ILAE), 17
IS. see infantile spasms (IS)
Johns Hopkins MAD protocol
adjustments, 90–91
diet prescription
carbohydrate, 90
energy, 90
fat, 90

Index

Johns Hopkins MAD protocol (cont’d)
fluid intake, 90
protein, 89
vitamins and minerals, 90
fine tuning, 91
follow-up, 91

KD. see ketogenic diet (KD)
KD therapy, Africa, 215–19
food choices, 216–17
implementation, 217–18
modified diets, 218
KD therapy, East Asia, 206–14
anecdotal experiences, 207
diverse KD menus
keto-cookie, 211
keto-dim sum, 212
keto-salmon-roll, 211
keto-shake, 212
keto-summer-roll, 210
food culture, 206
implementation, 207–9
liquid formula, milk, 209–10
modified Atkins diet, 213
KD therapy, India, 198–205
adolescents and infants, 199
blood ketones, efficacy improvement, 201, 203
high PUFA, efficacy improvement, 201–4
ketogenic ratio values, 198
normalization of lipids, 200–201
soy usage, 199
spices usage, 200
uric acid maintenance, 201
ketocal, 90, 124–30, 183–4, 185, 234
ketogenic diet (KD)
adults. see adult epilepsy, dietary treatment
Africa. see KD therapy, Africa
application and availability, 7–8
classical KD, 66–77
calculation, 66–73
composition, 5
defined, 4–6
diet ratio, 68, 69
dietary unit, 69, 70
exchanges, 74–6, 75, 76
meals and snacks, 71–3
protein prescription, 67, 68
computer programs, 71
East Asia. see KD therapy, East Asia
energy prescription, 66–7
enteral feeds. see enteral feeding
India. see KD therapy, India
infants. see infant epilepsy, dietary treatment
initiation, 131–4
ketoshake meal replacements, 74, 85–6
management. see dietary treatments, management
medium-chain triglyceride ketogenic diet (MCT KD), 78–88
calculation, 85
composition, 5
daily meal plan, 80–81, 86
defined, 4–6
dietary prescription, 78, 80
energy prescription, 78, 79
exchanges, 81–4, 82
snack recipes, 87–8
mechanisms of action. see mechanisms of action, dietary treatments
milk-free ketogenic diet, 114
monitoring. see monitoring, dietary treatments
ketone bodies, 3–4, 35–9, 36, 38–9
ketone monitoring
blood measurement. see blood measurement, ketosis
urine ketones. see urine ketones measurement
ketonia, 209, 209
ketoshake meal replacements
classical KD, 74, 74
MCT KD, 85–6
kidney stones, 152
Krebs cycle, 36, 37–9
Lennox-Gaustaut syndrome, 27
LGIT. see low glycaemic index treatment (LGIT)
Low glycaemic index treatment (LGIT) composition, 5, 103
description, 6, 100
discontinuation, 106–7
efficacy, 101–2
example calculation and menu, 104
fine tuning, 103, 105
follow-up, 103
glycaemic index (GI) value, 100–101
micronutrient supplementation, 105
protocols, adolescents and adults, 7
sick day management, 106
side effects, 106

MAD. see modified Atkins diet (MAD)
Magnetic resonance imaging (MRI), 13, 22
MCT. see medium-chain triglyceride (MCT)
mechanisms of action, dietary treatments, 37–41, 38
glycolysis, ketone bodies and Krebs cycle function, 37–9
mitochondria and bioenergetics, 40
neurotransmitter systems, 40
polyunsaturated fatty acids, 39–40
regulators of metabolism, 40–41
medium-chain triglyceride (MCT) constituents, 5
metabolism, 5–6, 35–6
medium-chain triglyceride ketogenic diet (MCT KD). see ketogenic diets, medium-chain triglyceride (MCT) diet
metabolic acidosis. see acidosis
micronutrient supplementation, 105, 109–10
milk-free classical ketogenic diet, 114
‘Miracle noodles’, 120
mitochondrial cytopathies, 228
mixed oil KD (MOKD), 201, 202
modified Atkins diet (MAD) adult treatment, 193–4, 190, 195
composition, 5
description, 6
efficacy, 28–9, 213
enteral feeding, 129
excessive protein intake, 143
implementation using food choice method, 92–7
calculation, 93
carbohydrate, 94, 95, 96
energy, 96
fat, 92, 94
fluid intake, 97
meal plan, 93
protein, 92, 94
inadequate protein and fat intake, 144
Johns Hopkins protocol. see Johns Hopkins MAD protocol
MCT addition, 146
recipes, 97
weight loss, 147–8
monitoring, dietary treatments, 149–52
echocardiography, 155
efficacy, 151
growth, 151–2
haematology and biochemistry blood investigations, 150
calcium/creatinine ratio, 152
elevated serum cholesterol and triglyceride levels, 149
fat-soluble vitamins, 151
omega-3 to omega-6 fatty acids ratio, 150
urine test, 152
monounsaturated fatty acids (MUFA), 200–201
MRI. see magnetic resonance imaging (MRI)
MUFA. see monounsaturated fatty acids (MUFA)
‘Net carbs’, 112
neurometabolic disease, KD therapy, 220–224
GLUT1 deficiency syndrome. see glucose transporter type 1 (GLUT1) deficiency syndrome
PDHD. see pyruvate dehydrogenase deficiency (PDHD)
potential long-term consequences, 220–221
neuroprotective activity of KD, 225
neurotrauma, 228
oligoantigenic diets, epilepsy, 7
osteoporosis
defined, 159
vitamin D, 159
paediatric epilepsy clinic, treatment options, 19–23
AEDs, 19
side effects, 19, 20
DBS and VNS, 21, 22
dietary therapy, 20
guidelines, National Institute for Health and Clinical Excellence (NICE), 19
palliative care, 22–3
defined, 22
surgery, 21
Parkinson disease (PD), 226–7
PBM. see peak bone mass (PBM)
PD. see Parkinson disease (PD)
PDHD. see pyruvate dehydrogenase deficiency (PDHD)
peak bone mass (PBM), 160
Phlexy-Vits, 109, 126, 128, 234
polyunsaturated fatty acids (PUFA)
efficacy improvement, 201–4
mechanism of KD action, 39–40
plasma lipid levels, 201, 202
post-ischaemia models, 227–8
pre-diet evaluation, 48–51
pre-existing feeding problems, children, 58–65
ASD. see autistic spectrum disorder (ASD)

behavioural categories, 61
management, 61, 63
planning diet, 61, 62
growth and energy requirements, 60–61
physical and epilepsy, 59
planning and instituting KD therapy, 59–60
preparation, dietary treatment, 47–57, 117–19
assessment, suitability
indications and contraindications, KD, 47, 48
other problems, 47–8
choosing a KD therapy, 53, 54
families
commitment and support, 117–18
multidisciplinary clinic, 52
realistic expectations, 52, 117
laboratory tests and medical investigations, 51–2
pre-diet meal manipulation, 53–4
pre-diet evaluation
clinical nurse specialist assessment and education, 50
dietetic/nutritional assessment, 49
dietetic assistant, 50–51
neurological and epilepsy, paediatric neurologist assessment, 49–50
shopping, 118–19
protein intake, safe levels, 68
pyruvate dehydrogenase deficiency (PDHD), 27, 181–2, 222–3

Rett syndrome, 28
saturated fatty acids (SFA)
and lipid levels, 149, 200–201
selenium deficiency, 150–151
soy, 199
spices
cumin seeds, 200
saffron, 200
turmeric, 200
switching, dietary treatments, 172–3
thickeners, for KD feeds, 60, 129
TSC. see tuberous sclerosis complex (TSC)
tuberous sclerosis complex (TSC), 28
urine ketones measurement
  abnormal/inaccurate results, 136
  babies and children in nappies, 135–6
  limitations, 136
  process, 135
vagal nerve stimulation (VNS), 21–2
vitamin and mineral supplemenation. see micronutrient supplementation
VNS. see vagal nerve stimulation (VNS)
weaning, enteral feeds, 130
weaning, infants, 185–6